Our Vision
Redefining What’s Drug-Accessible
Our vision is to make cytosolic delivery a solved problem, and to prove it by building our own precision oncology therapies on it, starting with TDOX.
SCROLL
The Opportunity
Most High-Value Targets Are Inside the Cell
Many of the most important oncology targets remain difficult to drug because therapeutic payloads cannot reliably reach the cytosol. Solving that barrier has the potential to expand the range of treatable targets and therapeutic approaches.
The Cytosolic Delivery Problem
Oncology drug discovery continues to identify proteins to degrade, silence, or inhibit. But many of these programs fail to translate because the therapeutic does not reliably reach its intracellular site of action. XELCIS XB is designed to close that gap.
Our Approach
Delivery as Foundational Infrastructure
Xelcis is building both a delivery platform and its own therapeutics on it. The platform supports multiple modalities, targets, and partner programs, and we are proving it first through our own pipeline, led by TDOX and two dual-payload combination programs.
Programs and Platform
A single enabling technology with leverage across the oncology landscape, proven through our own programs first. Each validated modality expands the platform's reach and the value we can build or license.
Built to Partner
Beyond our own pipeline, XELCIS XB is built to integrate into partner programs, adding delivery capability to assets already in development.
Capital-Efficient by Design
Advancing our own programs alongside a licensing and collaboration model lets us build value directly while partners validate their own targets, expanding the platform data set and commercial opportunity.
Precision Delivery
Engineered for Cytosolic Delivery
XELCIS XB is designed to overcome endosomal entrapment and deliver payloads to the cytosol with selectivity and functional relevance.
Long-Term Vision
A Platform for the Next Generation of Oncology
If cytosolic delivery can be made reliable and scalable, the impact extends far beyond any single program.
Enable Previously Inaccessible Targets
Targets long considered difficult to drug may become actionable when cytosolic delivery is solved.
Improve Success Rates Across Therapeutic Classes
By addressing a core cause of failure, XELCIS XB has the potential to improve success rates across multiple oncology modalities.
Foundational Delivery Technology
Like GalNAc in RNA therapeutics, XELCIS XB aims to become enabling delivery infrastructure for oncology, powering our own programs and partner programs that depend on cytosolic access.
